Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Alterola Biotech, Inc. ABTI OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • GB • USD

SharesGrow Score
23/100
0/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Alterola Biotech, Inc. (ABTI) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.01. It has a SharesGrow Score of 21/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net income is $2M (loss), growing at -1187.7%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $1M against $10M equity (Debt-to-Equity (D/E) ratio 0.14, conservative). Current ratio is 0.11 (tight liquidity). Debt-to-assets is 11.4%. Total assets: $12M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 28/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

ABTI SharesGrow Score Overview

31/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ABTI

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
ABTI: +0%/yr revenue is, -1187.7%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet ABTI: Debt-to-Equity (D/E) ratio 0.14 (conservative), Current ratio is 0.11 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
ABTI: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.0002-0.2
Volume20
Avg Volume (30D)2.73K
Market Cap$7.44M
Beta (1Y)1.43
Share Statistics
EPS (TTM)0.00
Shares Outstanding$806.33M
IPO Date2010-05-05
Employees1
CEODavid John Hitchcock
Financial Highlights & Ratios
EBITDA$-1.7M
Net Income$-1.54M
Operating Income$-1.9M
Total Cash$8.89K
Total Debt$1.41M
Net Debt$1.41M
Total Assets$12.38M
Price / Earnings (P/E)-2.7
Analyst Forecast
Company Info
CountryGB
ExchangeOther OTC
CurrencyUSD
ISINUS02152V1035

Price Chart

Track all markets on TradingView
ABTI
Alterola Biotech, Inc. ↗  ·  Other OTC
Healthcare • Drug Manufacturers - Specialty & Generic
0.00 52WK RANGE 0.20

People Also View

APNHF
APNHF
Aspen Pharmacare Holdings Limited
$8.69
+5.98%
 ATHJF
ATHJF
Antisense Therapeutics Limited
$0.01
-76.00%
 CRRTF
CRRTF
Crescita Therapeutics Inc.
$0.54
+0.00%
 BCBCF
BCBCF
The BC Bud Corporation
$0.04
-3.31%
 ANTCF
ANTCF
Aion Therapeutic Inc.
$0.00
+0.00%
 AXRX
AXRX
Amexdrug Corporation
$0.00
+0.00%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message